Nakamura Yuya, Suzuki Shinya, Murakami Shinnosuke, Nishimoto Yuichiro, Higashi Koichi, Watarai Naoki, Umetsu Junpei, Ishii Chiharu, Ito Yutaro, Mori Yuka, Kohno Mamiko, Yamada Takuji, Fukuda Shinji
Metagen Inc., 246-2 Kakuganji, Tsuruoka, Yamagata 997-0052, Japan.
Department of Life Science and Technology, Tokyo Institute of Technology, 2-12-1 Ookayama, Meguro-ku, Tokyo 152-8550, Japan.
Comput Struct Biotechnol J. 2022 Oct 25;20:5847-5858. doi: 10.1016/j.csbj.2022.10.026. eCollection 2022.
BB536 supplementation can be used to regulate bowel movements in various people, including healthy subjects and patients with irritable bowel syndrome (IBS); however, individuals vary in their responses to BB536 treatment. One putative factor is the gut microbiota; recent studies have reported that the gut microbiota mediates the effects of diet or drugs on the host. Here, we investigated intestinal features, such as the microbiome and metabolome, related to BB536 effectiveness in increasing bowel movement frequency.
A randomized, double-blind controlled crossover trial was conducted with 24 adults who mainly tended to be constipated. The subjects received a two-week dietary intervention consisting of BB536 in acid-resistant seamless capsules or similarly encapsulated starch powder as the placebo control. Bowel movement frequency was recorded daily, and fecal samples were collected at several time points, and analyzed by metabologenomic approach that consists of an integrated analysis of metabolome data obtained using mass spectrometry and microbiome data obtained using high-throughput sequencing. There were differences among subjects in intake-induced bowel movement frequency. The responders were predicted by machine learning based on the microbiome and metabolome features of the fecal samples collected before intake. The abundances of eight bacterial genera were significantly different between responders and nonresponders.
Intestinal microbiome and metabolome profiles might be utilized as potential markers of improved bowel movement after BB536 supplementation. These findings have implications for the development of personalized probiotic treatments.
补充BB536可用于调节各类人群的排便，包括健康受试者和肠易激综合征（IBS）患者；然而，个体对BB536治疗的反应存在差异。一个可能的因素是肠道微生物群；最近的研究报告称，肠道微生物群介导饮食或药物对宿主的作用。在此，我们研究了与BB536增加排便频率有效性相关的肠道特征，如微生物组和代谢组。
对24名主要倾向于便秘的成年人进行了一项随机、双盲对照交叉试验。受试者接受了为期两周的饮食干预，干预内容为服用装在耐酸无缝胶囊中的BB536或同样封装的淀粉粉末作为安慰剂对照。每天记录排便频率，并在几个时间点采集粪便样本，采用代谢基因组学方法进行分析，该方法包括对使用质谱获得的代谢组数据和使用高通量测序获得的微生物组数据进行综合分析。摄入后引起的排便频率在受试者之间存在差异。根据摄入前采集的粪便样本的微生物组和代谢组特征，通过机器学习预测应答者。应答者和非应答者之间有8个细菌属的丰度存在显著差异。
肠道微生物组和代谢组谱可能被用作补充BB536后排便改善的潜在标志物。这些发现对个性化益生菌治疗的开发具有启示意义。
